Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Petit A, Castillo M, Gaspa A, Colomer D, Garcia de Albeniz X, Moreno C, Camos M, Mellado B, Mallofre C. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. Histopathology. 2009 Aug;55(2):230-2. doi: 10.1111/j.1365-2559.2009.03342.x
Fenton M, Huang H, Hong Y, Hawe E, Kurz DJ, Erusalimsky JD. Early atherogenesis in senescence-accelerated mice. Exp Gerontol. 2004;39(1):115-22.